Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)

NCT02437591 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammatory Bowel Disease (IBD)
Clostridium Difficile Infection (CDI)

Interventions

DRUG: fidaxomicin

Sponsor

Astellas Pharma Europe Ltd.